Recommendations,Strength rating
New 2023 recommendation: Offer adjuvant platinum-based chemotherapy after RNU   to patients with pT2â€“T4 and/or pN+ disease.,Strong
"New 2023 recommendation: Discuss adjuvant nivolumab with patients unfit   for, or who declined, platinum-based adjuvant chemotherapy for > pT3 and/or   pN+ disease after RNU alone or > ypT2 and/or ypN+ disease after neoadjuvant   chemotherapy, followed by RNU.",Weak
"2022 recommendation: Offer kidney-sparing management to patients with solitary   kidney and/or impaired renal function, providing that it will not compromise survival.   This decision will have to be made on a case-by-case basis in consultation with the   patient.",Strong
"Revised 2023 recommendation: Offer kidney-sparing management to high-risk   patients with imperative indication on a case-by-case basis, in consultation with the   patient.",Strong
